Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Ophthalmologists implant five patients with artificial silicon retina microchip

29.04.2005


Solar Cell Implant May Restore Some Sight for the Blind



Ophthalmologists at Rush University Medical Center implanted Artificial Silicon Retina (ASR) microchips in the eyes of five patients to treat vision loss caused by retinitis pigmentosa (RP). The implant is a silicon microchip 2mm in diameter and one-thousandth of an inch thick, less than the thickness of a human hair. Four patients had surgery Tuesday, January 25. The fifth patient is scheduled for a later date.

Rush principal investigator Dr. John Pollack performed the surgeries with Dr. Kirk Packo, Dr. Pauline Merrill, Dr. Mathew MacCumber, and Dr. Jack Cohen. All are members of Illinois Retina Associates, S.C., a private practice group and are on the Rush faculty. Patients leave the hospital the same day and will be followed for two years as part of the study, and then indefinitely. The patients were recruited from a pool of about 5,000 applicants.


The implants are designed for people with retinal diseases such as macular degeneration and retinitis pigmentosa, which cause blindness and vision impairment in about 10 million Americans. More than one million of these people are legally blind.

"As is commonly seen in with retinitis pigmentosa, these patients all have severe narrowing of their visual fields down to a very small central circle, and all patients in the study are legally blind," says Pollack.

The Artificial Silicon RetinaTM (ASR) was invented by Dr. Alan Chow, pediatric ophthalmologist and Rush faculty member, who developed the chip and founded Optobionics, with his brother Vincent, vice president of engineering. Optobionics is located in Naperville, Illinois.

"This is an expansion of the study of the first 10 patients completed in 2002," says study investigator Dr. Kirk Packo, who oversees the three participating sites. The sites are Johns Hopkins School of Medicine, Baltimore, Emory University School of Medicine/Atlanta VA Medical Center and Rush.

Pollack says the current protocol has been modified to reduce the likelihood of inadvertant scientific bias. "We operated on the right eye of each of the initial 10 patients. For the next 20 patients we will randomly select which eye will receive the ASR chip. In addition, post-operative vision testers will be masked as to which eye received the ASR chip implant. The current study is being performed at these study centers in order to independently validate previous studies performed by Optobionics."

The first 10 patients all reported some degree of improvement in visual function, says Pollack. "Improvement in visual function was variable and included the ability to read letters, improvement in color vision, and expansion of their visual field. Some patients gained new ability to recognize facial features -- something that they were unable to do before ASR chip implantation. Some patients have experienced improvement in activities of daily living such as improved ambulation-not bumping into objects around the house, and reading the time on a clock."

Still in Phase II clinical trials, Pollack cautions it is still too early to determine what percentage of patients might experience improvement in vision and what resolution capability these patients might eventually have. "Although we hope that all patients receiving the chip will experience some improvement in visual function, we can’t say for sure how these patients will respond to this new treatment since this is still an experimental trial. If this study and future studies show safety and efficacy of the chip and it’s approved by the FDA, it could be as soon as three to five years that this technology would be available to others."

Surgical Information

The ASR chip contains approximately 5,000 microscopic solar cells that convert light into electrical impulses. The purpose of the chip is to replace damaged photoreceptors, the "light-sensing" cells of the eye, which normally convert light into electrical signals within the retina. Loss of photoreceptor cells occurs in persons with retinitis pigmentosa (RP) and other retinal diseases.

The microsurgical procedure starts with three tiny incisions in the white part of the subject’s eye, each incision no larger than the diameter of a needle. Through these incisions, the surgeons insert a miniature cutting and vacuuming device that removes the gel in the middle of the eye and replaces it with saline. They then make a pinpoint opening in the retina through which they inject fluid to lift up a portion of the retina from the back of the eye, creating a small pocket in the "subretinal space" just wide enough to accommodate the ASR.

The surgeons then enlarge the pocket opening and insert the implant into the subretinal space. Finally, they reseal the retina over the ASR, insert air into the middle of the eye to gently push the retina back down over the device, and close the incisions. Over a period of 1 week the air bubble is resorbed and replaced by fluids created within the eye.

According to Chow, "The use of the subretinal space to hold a device that artificially stimulates the retina seems a logical step in replacing the loss of photoreceptor cells of the retina. If the implant is tolerated well and is able to successfully stimulate the retina, it may open up new opportunities for restoring sight in patients with the end stages of retinitis pigmentosa."

Mary Ann Schultz | EurekAlert!
Further information:
http://www.rush.edu

More articles from Health and Medicine:

nachricht New malaria analysis method reveals disease severity in minutes
14.08.2017 | University of British Columbia

nachricht New type of blood cells work as indicators of autoimmunity
14.08.2017 | Instituto de Medicina Molecular

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Fizzy soda water could be key to clean manufacture of flat wonder material: Graphene

Whether you call it effervescent, fizzy, or sparkling, carbonated water is making a comeback as a beverage. Aside from quenching thirst, researchers at the University of Illinois at Urbana-Champaign have discovered a new use for these "bubbly" concoctions that will have major impact on the manufacturer of the world's thinnest, flattest, and one most useful materials -- graphene.

As graphene's popularity grows as an advanced "wonder" material, the speed and quality at which it can be manufactured will be paramount. With that in mind,...

Im Focus: Exotic quantum states made from light: Physicists create optical “wells” for a super-photon

Physicists at the University of Bonn have managed to create optical hollows and more complex patterns into which the light of a Bose-Einstein condensate flows. The creation of such highly low-loss structures for light is a prerequisite for complex light circuits, such as for quantum information processing for a new generation of computers. The researchers are now presenting their results in the journal Nature Photonics.

Light particles (photons) occur as tiny, indivisible portions. Many thousands of these light portions can be merged to form a single super-photon if they are...

Im Focus: Circular RNA linked to brain function

For the first time, scientists have shown that circular RNA is linked to brain function. When a RNA molecule called Cdr1as was deleted from the genome of mice, the animals had problems filtering out unnecessary information – like patients suffering from neuropsychiatric disorders.

While hundreds of circular RNAs (circRNAs) are abundant in mammalian brains, one big question has remained unanswered: What are they actually good for? In the...

Im Focus: RAVAN CubeSat measures Earth's outgoing energy

An experimental small satellite has successfully collected and delivered data on a key measurement for predicting changes in Earth's climate.

The Radiometer Assessment using Vertically Aligned Nanotubes (RAVAN) CubeSat was launched into low-Earth orbit on Nov. 11, 2016, in order to test new...

Im Focus: Scientists shine new light on the “other high temperature superconductor”

A study led by scientists of the Max Planck Institute for the Structure and Dynamics of Matter (MPSD) at the Center for Free-Electron Laser Science in Hamburg presents evidence of the coexistence of superconductivity and “charge-density-waves” in compounds of the poorly-studied family of bismuthates. This observation opens up new perspectives for a deeper understanding of the phenomenon of high-temperature superconductivity, a topic which is at the core of condensed matter research since more than 30 years. The paper by Nicoletti et al has been published in the PNAS.

Since the beginning of the 20th century, superconductivity had been observed in some metals at temperatures only a few degrees above the absolute zero (minus...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Call for Papers – ICNFT 2018, 5th International Conference on New Forming Technology

16.08.2017 | Event News

Sustainability is the business model of tomorrow

04.08.2017 | Event News

Clash of Realities 2017: Registration now open. International Conference at TH Köln

26.07.2017 | Event News

 
Latest News

Gold shines through properties of nano biosensors

17.08.2017 | Physics and Astronomy

Greenland ice flow likely to speed up: New data assert glaciers move over sediment, which gets more slippery as it gets wetter

17.08.2017 | Earth Sciences

Mars 2020 mission to use smart methods to seek signs of past life

17.08.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>